Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) and William Ackman’s hedge fund Pershing Square Capital Management reportedly agreed to split litigation costs in a class action lawsuit brought on by shareholders over an alleged insider trading scheme in Allergan (NYSE:AGN)’s 2014 takeover bid.
In June 2014, Valeant offered a tender bid for Allergan, which was followed by a 7 month-long hostile pursuit by Valeant and Ackman’s hedge fund. In November 2014, Allergan publicly announced that it had accepted a $66 billion takeover bid from Actavis.
Get the full story at our sister site, Drug Delivery Business News.